Here we'll explore the nexus of legal rulings, Capitol Hill
policy-making, technical standards development, and technological
innovation that creates -- and will recreate -- the networked world as we
know it. Among the topics we'll touch on: intellectual property
conflicts, technical architecture and innovation, the evolution of
copyright, private vs. public interests in Net policy-making, lobbying
and the law, and more.
Disclaimer: the opinions expressed in this weblog are those of the authors and not of their respective institutions.
Geist says that the Court's decision rested on the notion that the patent claims themselves were not sufficient descriptive to permit a skilled person to replicate the invention that is supposedly disclosed. Patent critics have for many years railed against badly written patent claims and the fact that examiners, particularly in the US, seem willing to let patents go with badly drafted claims. Here we have a clear situation of a high Court rejecting that kind of sloppy (inadequate) patent claims construction.
I don't think that the Canadian decision will affect Pfizer's patents in other countries (e.g. the US) but practically once a generic version of a drug is manufactured it's impossible to stop its trans-national shipment. Gods help us we'll probably see an uptick in spam emails for "generic Viagra" now.